Tadalafil Tablet, Film Coated
Product Images NDC 72303-0823

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72303-0823). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hec Pharm Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

A0f6fc35 4b63 38bf E053 2995a90a8be2

A0f6fc35 4b63 38bf E053 2995a90a8be2
This text provides information on a medication that comes in tablet form and contains 2.5 mg of an active ingredient. The usual dosage guidance can be found on the accompanying NDC label. It is recommended to store the tablets at a temperature range between 20°C to 25°C, with excursions allowed between 15°C to 30°C. The medication is for once daily use and should not be split. The tablets should be kept out of reach of children and dispensed in a tight container. The manufacturer is HEC Pharma USA Inc., and the tablets are manufactured by Sunshine Lake Pharma Co, Ltd in Guangdong Province, China. The entire dose should be taken, and the packaging contains 30 tablets.*
FDA Label Image

Logo0001-01 (01)

FDA Label Image

Logo0001-01 (02)

FDA Label Image

Logo0001-01 (03)

FDA Label Image

Logo0001-01 (07)

FDA Label Image

10mg-30 (Tadalafil 10mg 30ct 033 00)

10mg-30 (Tadalafil 10mg 30ct 033 00)
This text describes a medication called Tadalafil, available in 10 mg tablets. The suggested storage temperature is between 20°C to 25°C with excursions permitted. It contains a warning to keep out of reach of children and to dispense in a tight container. The manufacturer is HEC Pharma USA Inc and it is manufactured by Sunshine Lake Pharma Co, Ltd in Guangdong Province, China. The medication should not be split, and the entire dose should be taken. The package contains 30 tablets.*
FDA Label Image

20mg-30 (Tadalafil 20mg 30ct 034 00)

20mg-30 (Tadalafil 20mg 30ct 034 00)
This text provides important information about a medication containing 20 mg of tadalafil. It specifies the storage conditions, dosage instructions, manufacturer details, and warnings to keep the tablets out of reach of children. It also states that the tablets should not be split and the entire dose should be taken.*
FDA Label Image

20mg-60 (Tadalafil 20mg 60ct 034 00)

20mg-60 (Tadalafil 20mg 60ct 034 00)
This text provides essential information about a medication called Tadalafil in tablet form. It includes details about the dosage, storage recommendations, manufacturer's information, and a warning to keep the product out of children's reach. The medication is manufactured by HEC Pharma USA Inc. and Sunshine Lake Pharma Co., Ltd from Guangdong Province, China. The tablets contain 20 mg of Tadalafil and come in a pack of 60 tablets. It is essential to take the entire dose without splitting the tablets.*
FDA Label Image

5mg-30 (Tadalafil 2point5mg 30ct 031 00)

5mg-30 (Tadalafil 2point5mg 30ct 031 00)
This text provides information about a medication that comes in tablet form and contains 2.5 mg of an active ingredient. The usual dosage instructions can be found on the accompanying NDC, and the tablets should be stored at a temperature range of 20°C to 25°C. It warns to keep out of reach of children and advises against splitting the tablets. The medication is meant for once-daily use, and the entire dose should be taken. It is manufactured by HEC Pharma USA Inc. and Sunshine Lake Pharma Co, Ltd. The packaging contains 30 tablets and should be dispensed in a tight container.*
FDA Label Image

5mg-30 (Tadalafil 5mg 30ct 032 00)

5mg-30 (Tadalafil 5mg 30ct 032 00)
This text provides dosing information for Tadalafil tablets, each containing 5 mg of the active ingredient. It also includes storage guidelines and a warning to keep the product out of reach of children. The manufacturing details for the product are included, along with a National Drug Code (NDC) number for identification purposes. Additionally, it advises against splitting the tablets, recommending that the entire dose should be taken. The product is identified as being for prescription use only and comes in a package of 30 tablets.*
FDA Label Image

Chemical Structure (Tadalafil Uspi F001 Structure V1)

FDA Label Image

Figure (Tadalafil Uspi F001 V2)

Figure (Tadalafil Uspi F001 V2)
This is a chart showing the plasma tadalafil concentration (in micrograms per liter) over time in hours after different doses of tadalafil were administered. It includes a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The chart shows the concentration levels at various time points up to 120 hours.*
FDA Label Image

Figure (Tadalafil Uspi F002 V1)

Figure (Tadalafil Uspi F002 V1)
This text provides data on the difference in blood pressure (mmHg) between Tadalafil and Placebo. It includes readings for Standing Systolic and Diastolic BP, as well as Supine Systolic and Diastolic BP over a period of time.*
FDA Label Image

Figure (Tadalafil Uspi F003 V1)

FDA Label Image

Figure (Tadalafil Uspi F004 V1)

Figure (Tadalafil Uspi F004 V1)
The text describes a study involving the administration of different medications for evaluating systolic blood pressure (BP) in patients. The study involves dosages of 20 mg tadalafil and 8 mg qd doxazosin at different times. The comparison is made between tadalafil and placebo along with the doxazosin. The study tracks the systolic BP readings at various time points after the administration of tadalafil or placebo.*
FDA Label Image

Figure 5 (Tadalafil Uspi F005 V1)

Figure 5 (Tadalafil Uspi F005 V1)
This document shows changes in the IPSS Total Score over a 12-week treatment period with Tadalafil 5 mg compared to a Placebo. The chart indicates a statistically significant improvement in symptoms, with the asterisk denoting a p-value of less than 0.01.*
FDA Label Image

Figure 6 (Tadalafil Uspi F006 V1)

Figure 6 (Tadalafil Uspi F006 V1)
Change from Baseline in IPSS Total Score comparing Tadalafil 5 mg versus Placebo for a certain duration of treatment in weeks. The statistical significance is denoted by *p<0.01.*
FDA Label Image

Figure 7 (Tadalafil Uspi F007 V2)

FDA Label Image

Figure 8 (Tadalafil Uspi F008 V1)

Figure 8 (Tadalafil Uspi F008 V1)
This description mentions the change from baseline in IPSS total score after 12 weeks of treatment with Tadalafil 5 mg compared to a Placebo. The statistical significance (p<0.01) indicates that there was a significant difference between the treatment groups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.